Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...

In the throes of winter's yearly round of respiratory virus outbreaks, it pays to remember what Grandma told you.

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

RSV is a contagious virus causing severe respiratory infections in infants. Vaccination during pregnancy, provides newborns ...